Click to see our news releases about special projects and other announcements.Read More
Journalists: We are at your service. Please contact us with your request.Connect
ISB researchers have found that a small, persistent increase in the expression of NOD1 could be responsible for higher cancer risks. The research team found that a slight 1.5-fold uptick in NOD1 expression can activate the protein and downstream signaling pathways in a manner similar to vast (30- to 200-fold) overexpression.
In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.
Members of ISB’s Heath Lab and their collaborators have developed a way to sensitively detect and analyze neoantigen-specific T-cell populations from tumors and blood. This promising development may have implications for creating targeted, individual-specific cancer vaccines.
ISB’s Dr. Sui Huang uses the theory of complex systems and applies it to cancer research. In this video Q&A, he discusses the cancer paradox and highlights the importance of understanding the mechanism of what cancer treatments can backfire in order to open a new avenue for therapy and treatments.
The Andy Hill Cancer Research Endowment (CARE) is a public-private partnership that supports cancer research in Washington state. CARE announced ISB Assistant Professor Dr. Wei Wei as a CARE Fund Distinguished Researcher and awarded him $500,000.
ISB’s Professor Sui Huang, MD, PhD, has been announced by Cancer Research UK as a member of a global research team funded through its Grand Challenge competition — an international funding initiative that aims to answer some of the biggest questions facing cancer research.
The Andy Hill Cancer Research Endowment (CARE) announced $750,000 in grant funding for Dr. Jim Heath’s work on proactive cancer immunotherapies for initial and recurrent disease. This is the first stage of a planned longer program led by Jim and ISB, and involving Swedish Cancer Institute, Earl A. Chiles Research Institute in Portland, and UW Medicine.
Dead cells, or cell debris, generated by treatments intended to eradicate tumor cells actually act as strong stimulators of tumor progression. The findings of ISB cancer biologist Sui Huang, his former mentee and longtime collaborator Dipak Panigrahy at Beth Isreal Deaconess Medical Center in Boston, and colleagues at Harvard Medical School were published in The Journal of Experimental Medicine.
April 25, 2017 A Cell-Surface Membrane Protein Signature for Glioblastoma 3 bullets: Using integrated protein and gene expression data, ISB researchers developed a 33-gene signature for glioblastoma, an aggressive form of brain cancer. Glioblastoma gene signatures are associated with TGF-b signaling and cancer invasion. Researchers think that some of the glioblastoma gene signatures have the potential to be used as blood biomarkers for this aggressive cancer. Read the full summary…
The Baliga Lab’s Dr. Christopher Plaisier was the lead author of the study “Causal Mechanistic Regulatory Network for Glioblastoma Deciphered Using Systems Genetics Network Analysis” which published online in Cell Systems on July 14. Dr. Plaisier wrote a summary of the research: 3 Bullets: Using data from TCGA and ENCODE, ISB researchers developed integrative database and analysis platforms that provide insight about the underpinnings of glioblastoma multiforme. Researchers developed a…
The journal Cell published a study today (July 7) about the integrated analysis of drug response in 1,001 cancer cell lines. This study was undertaken by a large international group of researchers including ISB Senior Research Scientist Theo Knijnenburg. The researchers integrated heterogeneous molecular data of 11,215 tumors and 1,001 cell lines in order to study the drug response of these cell lines to 265 anti-cancer drugs. They uncovered numerous…
As part of The Cancer Genome Atlas project, the Shmuelvich Lab and colleagues published a paper in the journal Cancer Cell related to the rare cancer adrenocortical carcinoma. Read the summary: 3 Bullets: Adrenocortical carcinoma (ACC) is a rare, under-researched endocrine cancer with limited therapeutic options and overall poor outcome. TCGA researchers performed comprehensive analysis of 91 ACC samples to gain better understanding of potential genetic causes of the cancer….
ISB’s Dr. Ilya Shmulevich attended Google Cloud Platform’s GCPNext conference in San Francisco and presented on ISB’s Cancer Genomics Cloud project. He explains how his team used GCP to create better access for a broad range of researchers to cancer genomics data (from The Cancer Genomics Atlas) and the tools with which to explore that data. Watch Dr. Shmulevich’s talk below.
Cure First is hosting the forum “Cancer Think Tank.” Speakers include ISB’s Dr. Ilya Shmulevich and Dr. Brady Bernard. Date: January 21, 2016 Time: 1-5:30 p.m. MED talks, breakout sessions, and panel discussion; 6-8 p.m. networking with wine and dinner Why: To jump start innovative collaborations in cancer research with the goal to submit proposals for funding to accelerate the discovery of new, less toxic and targeted therapies. Who: This…
3 Bullets: Identifying the most aggressive cells in cancer (cancer stem cells) is essential for designing effective therapy and predicting patient outcomes. Using single-cell analysis techniques, researchers at ISB and Luxembourg Centre for Systems Biomedicine have identified the molecular signatures of two types of malignant breast tissue cells. Researchers found an interesting twist: the two cell types “cooperate” to increase malignancy potential and they promote a third hybrid stem-cell type….
Name: John Chevillet, PhD Lab: Hood Research: I am trying to develop an ultrasound-based method to take a sample from a tumor, thus replacing needle biopsies. An ultrasound-based method would minimize complications, better diagnose cancers, and direct the use of targeted therapies for personalized medicine. Wish List: If I had $10,000, I could analyze the blood specimens we currently have for cancer dna to demonstrate what this method can tell…
Congratulations to the Sui Huang Lab at ISB which has received a five-year $1.7 million R01 award from the National Institutes of Health and National Institute for General Medical Sciences to study cancer sub-population dynamics to understand and develop drugs to inhibit lethal cancer-drug resistance. The project proposal states that the work will: “develop a quantitative and formal framework for describing the temporal evolution of cell phenotype distribution in a…